Literature DB >> 17227899

The continuum of care: a paradigm for the management of metastatic colorectal cancer.

Richard M Goldberg1, Mace L Rothenberg, Eric Van Cutsem, Al B Benson, Charles D Blanke, Robert B Diasio, Axel Grothey, Heinz-Josef Lenz, Neal J Meropol, Ramesh K Ramanathan, Carlos H Roberto Becerra, Rita Wickham, Delma Armstrong, Carol Viele.   

Abstract

New agents for the treatment of metastatic colorectal cancer have extended median overall survival to more than 20 months, an increase that has changed the view of advanced colorectal cancer from an acute to a chronic condition. This article proposes a shift in treatment strategy from the concept of successive "lines" of therapy, in which chemotherapy is continued until disease progression, to that of a continuum of care, in which the use of chemotherapy is tailored to the clinical setting and includes switching chemotherapy prior to disease progression, maintenance therapy, drug "holidays," and surgical resection of metastases in selected patients. In this approach, the distinction between lines of therapy is no longer absolute. This represents a paradigm shift in the management of metastatic colorectal cancer to that of a continuum of care approach that includes individualized planning, in which patients are given the opportunity to benefit from exposure to all active agents and modalities while minimizing unnecessary treatment and toxicity, with the ultimate goal of improving survival as well as quality of life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17227899     DOI: 10.1634/theoncologist.12-1-38

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  69 in total

1.  Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.

Authors:  S Yousuf Zafar; Jennifer E Marcello; Jane L Wheeler; Krista L Rowe; Michael A Morse; James E Herndon; Amy P Abernethy
Journal:  J Oncol Pract       Date:  2009-09       Impact factor: 3.840

2.  Meta-analysis of survival of patients with stage 4 colorectal cancer managed with resection versus chemotherapy alone.

Authors:  Imran Hassan; Vriti Advani
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

3.  PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Authors:  Arjun Sood; Danielle McClain; Radhashree Maitra; Atrayee Basu-Mallick; Raviraja Seetharam; Andreas Kaubisch; Lakshmi Rajdev; John M Mariadason; Kathryn Tanaka; Sanjay Goel
Journal:  Clin Colorectal Cancer       Date:  2012-01-28       Impact factor: 4.481

4.  PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.

Authors:  Shuangjie Wu; Yu Gan; Xinhai Wang; Jun Liu; Mengjun Li; Yifan Tang
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-24       Impact factor: 4.553

Review 5.  Optimal management of metastatic colorectal cancer: current status.

Authors:  Autumn J McRee; Richard M Goldberg
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

6.  Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.

Authors:  Sunil K Geevarghese; David A Geller; Hans A de Haan; Markus Hörer; Anette E Knoll; Axel Mescheder; John Nemunaitis; Tony R Reid; Daniel Y Sze; Kenneth K Tanabe; Hoda Tawfik
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

7.  Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials.

Authors:  Chengyao Zhang; Jiawu Wang; Haitao Gu; Daihua Zhu; Yang Li; Peng Zhu; Yaxu Wang; Jijian Wang
Journal:  Oncol Lett       Date:  2012-01-16       Impact factor: 2.967

8.  Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study.

Authors:  Christopher C L Liao; Anuja Mehta; Nicholas J Ward; Simon Marsh; Tan Arulampalam; John D Norton
Journal:  World J Surg Oncol       Date:  2010-04-26       Impact factor: 2.754

9.  Mass spectrometry protein expression profiles in colorectal cancer tissue associated with clinico-pathological features of disease.

Authors:  Christopher C L Liao; Nicholas Ward; Simon Marsh; Tan Arulampalam; John D Norton
Journal:  BMC Cancer       Date:  2010-08-06       Impact factor: 4.430

Review 10.  Treatment of colorectal cancer in older patients.

Authors:  Riccardo A Audisio; Demetris Papamichael
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-09       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.